Study Design and Participants
From January 2014 to December 2015, 161 patients with unilateral SSNHL
accompanied by newly developed tinnitus who were hospitalized in the
Department of Otorhinolaryngology, Peking University People’s Hospital,
were enrolled. All of the patients’ hearing was assessed by the same
doctor. After admission, treatments were applied in accordance with the
Chinese Guideline for Sudden
Deafness(17). Systemic corticosteroids
and hemodilution agents were administered as therapeutic measures. All
patients received 40 mg of intravenous methylprednisolone for 5
consecutive days and hemodilution agents for 10 days, including 87.5 mg
of intravenous EGb-761(Dr. Willmar Schwabe GmbH & Co., Germany) every
day and 5 BU of intravenous batroxobin (Beijing Tobishi Pharmaceutical
Co.), the first dose was doubled, and every other day based on
fibrinogen levels.